Latest filing published 06 Sept 2019 for Harpoon Therapeutics, Inc., €91k.
Based on 6 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Gerald McMahon PhD is a declared insider at 4 companies; the most frequent names are Celldex Therapeutics, Inc., Neorx Corp and Harpoon Therapeutics, Inc. The record holds 39 filings, for trades running from 6 March 2008 to 5 June 2019.
Every open-market trade on record is a purchase: 9 purchases worth €52k, and no sale. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Besides market trades, the filings include 27 share grants and 3 option exercises. So far in 2019, the count stands at 3 purchases and no sales.
The median purchase comes to €7,354. None of the 3 purchases we analysed coincided with buying by another insider of the same company within 30 days. Ninety days after publication, 6 purchases show a median change of -17.6%, with the price up in 17% of them. These figures describe past trades and do not predict future prices.
The newest entry dates from 6 September 2019: an option exercise of €91k, in Harpoon Therapeutics, Inc. The last insider purchase was made public on 16 May 2019, 2,718 days ago. Typically, a trade is published a median of 1 day after it takes place. US insiders must file a Form 4 within two business days of a trade. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
25 of 39 declarations